Iovance Biotherapeutics, Inc. IOVA Tax on Share Settlement
Tax on Share Settlement at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s tax on share settlement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s tax on share settlement?
- Iovance Biotherapeutics, Inc. (IOVA) reported tax on share settlement of $4.18M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s tax on share settlement changed year-over-year?
- Iovance Biotherapeutics, Inc.'s tax on share settlement decreased by 26.0% year-over-year, from $5.64M to $4.18M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s tax on share settlement?
- Over 2 years (2023 to 2025), Iovance Biotherapeutics, Inc.'s tax on share settlement has grown at a 58.9% compound annual growth rate (CAGR), from $2.8M to $7.06M.
- What does tax on share settlement mean?
- Cash paid to tax authorities for employee share vesting, where the company withholds shares and pays the tax obligation in cash.